Johnson & Johnson MedTech's Next-Gen QDOT Micro Pressure-Sensing Radiofrequency Ablation Catheter Receives NMPA Approval in China

ShanghaiFebruary 23, 2023PR Newswire -- The latest generation of Johnson & Johnson Medical Technologies' disposable pressure monitoring radiofrequency ablation catheter (QDOT Micro Diagnostic/Ablation Deflectable Tip Catheter) has recently been officially approved for marketing in China by the National Medical Products Administration. This catheter provides a brand-new innovative solution for atrial fibrillation treatment.

Atrial fibrillation, also known as "AFib," is a common type of rapid arrhythmia disease and has become one of the cardiovascular conditions with the highest incidence rates in China. AFib not only can lead to cardiac-related complications such as sudden cardiac death and heart failure, but also increases the risk of stroke by five times.^[1], causing significant harm to patients' quality of life. According to statistics, there are currently more than 20 million people in China^[2]Patients. With the increase of age, the incidence of atrial fibrillation rises sharply, and the prevalence rate in the 75-84 age group even reaches 12%.^[3]Catheter radiofrequency ablation is one of the main treatment methods for atrial fibrillation currently, which involves inserting a radiofrequency ablation catheter into the heart through minimally invasive puncture, and then releasing radiofrequency energy to ablate the lesion. For a long time, the progress and innovation in the diagnosis and treatment of atrial fibrillation have been the focus of attention in the industry. QDOT Micro provides an innovative solution for atrial fibrillation treatment, bringing good news to Chinese patients with atrial fibrillation.

Johnson & Johnson Medical Technologies is always committed to enhancing the technology and standardized development of atrial fibrillation treatment in China. With the support of national policies, Johnson & Johnson Medical Technologies continuously accelerates the introduction of innovative products and surgical solutions into China. "At the 3rd CIIE in 2020, QDOT Micro made its debut in China. Two years later, QDOT Micro was officially approved, marking another innovative milestone for Johnson & Johnson Medical Technologies in the field of electrophysiology."Dr. Chen Xi, General Manager of Cardiovascular and Professional Solutions Division, Johnson & Johnson Medical Technology ChinaIntroduced, "With the acceleration of the aging process in China, the treatment needs of patients are also gradually increasing. We will continue to accelerate the introduction of innovative products in the electrophysiology field. Through products such as 3D magnetic navigation systems, ablation catheters and energy emitters, mapping catheters, and 3D intracardiac ultrasound catheters, we aim to create an integrated solution for arrhythmia diseases. We will also collaborate with multiple parties to provide standardized training for physicians, jointly promoting high-quality development in the electrophysiology field and safeguarding the cardiovascular health of the Chinese people."

^[1] D'Souza A, Butcher KS, Buck BH. The Multiple Causes of Stroke in Atrial Fibrillation: Thinking Broadly. Can J Cardiol. 2018;34(11):1503-1511. doi:10.1016/j.cjca.2018.08.036 https://pubmed.ncbi.nlm.nih.gov/30404753/#:~:text=Atrial%20fibrillation%20%28AF%29%20is%20numerically%20the%20most%20important,reduces%20the%20risk%20of%20stroke%20by%20approximately%20two-thirds

^[2] Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study：https://www.thelancet.com/action/showPdf?pii=S2666-6065%2822%2900054-2

^[3]Ma Changsheng. "Progress in the Epidemiology of Atrial Fibrillation."Medicine and Philosophy, 2016, 37(561):8-9